References
- Sharma D, Farahbakhsh N, Shastri S, et al. Intrauterine growth restriction – part 2. J Matern Fetal Neonatal Med. 2016;29:4037–4048.
- Zabransky S. Fetal growth restriction: definitions, causes, and epidemiology. In: Caring for children born small for gestational age. Springer Healthcare; 2013. p. 57–75.
- Ford JH. Preconception risk factors and SGA babies: papilloma virus, omega 3 and fat soluble vitamin deficiencies. Early Hum Dev. 2011;87:785–789.
- Karowicz-Bilińska A. The latent infection of human papilloma virus in pregnat woman and colonization of placenta – preliminary report. Ginekol Pol. 2007;78:966–970.
- Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004;23:569–578.
- Bruni R, Taliani G, Ciccaglione AR. Antiviral treatment of HBV positive pregnant women: an additional tool to reduce perinatal transmission. Pathog Glob Health. 2016;110:275–276.
- Hermonat PL, Kechelava S, Lowery CL, et al. Trophoblasts are the preferential target for human papilloma virus infection in spontaneously aborted products of conception. Hum Pathol. 1998;29:170–174.
- Gomez LM, Ma Y, Ho C, et al. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod. 2008;23:709–715.
- Zuo Z, Goel S, Carter JE. Association of cervical cytology and HPV DNA status during pregnancy with placental abnormalities and preterm birth. Am J Clin Pathol. 2011;136:260–265.
- Slatter TL, Hung NG, Clow WM, et al. A clinicopathological study of episomal papillomavirus infection of the human placenta and pregnancy complications. Mod Pathol. 2015;28:1369–1382.
- Souho T, Benlemlih M, Bennani B. Human papillomavirus infection and fertility alteration: a systematic review. PLoS One. 2015;10:e0126936.
- Dobbins TA, Sullivan EA, Roberts CL, et al. Australian national birthweight percentiles by sex and gestational age, 1998–2007. Med J Aust. 2012;197:291–294.
- Syrjänen S, Shabalova IP, Petrovichev N, et al. Human papillomavirus testing and conventional pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former soviet union. J Low Genit Tract Dis. 2002;6:97–110.
- De Vuyst H, Claeys P, Njiru S, et al. Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography. Int J Gynecol Obstet. 2005;89:120–126.
- Stevens MP, Garland SM, Tan JH, et al. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol. 2009;81:1283–1291.
- Melsheimer P, Kaul S, Dobeck S, et al. Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol. 2003;47:124–128.
- Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. Biochem Soc Trans. 2007;35:1456–1460.
- Doorbar J, Egawa N, Griffin H, et al. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25:2–23.
- Liu P, Xu L, Sun Y, et al. The prevalence and risk of human papillomavirus infection in pregnant women. Epidemiol Infect. 2014;142:1567–1578.
- Olmsted SS, Padgett JL, Yudin AI, et al. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J. 2001;81:1930–1937.
- Weyn C, Thomas D, Jani J, et al. Evidence of human papillomavirus in the placenta. J Infect Dis. 2011;203:341–343.
- Ambühl LM, Baandrup U, Dybkaer K, et al. Human papillomavirus infection as a possible cause of spontaneous abortion and spontaneous preterm delivery. Infect Dis Obstet Gynecol. 2016;2016:3086036.